unilife signs long-term supply contract, page-81

I agree clarity on revenue potential is lacking (and required) in the statement released from Unilife
There is clearly potential for significant revenue however as this is not a cheap drug:

(Wikipedia)
Cost and Market[edit source | editbeta]

A single 60 mg injection of Enoxaparin can cost $898.00 for the drug alone, as shown in a 2013 statement from a California hospital.
Annual sales approx $3.17 billion.[citation needed]
Enoxaparin is not protected by US patent due to inequitable conduct on the filing of Patent No. 5,389,618.[4]